Silja Chouquet examines the Twitter noise at pharma meetings and offers pointers to keep KOLs engaged while avoiding the attention of worthless click-farm accounts.
In its bid to satisfy investors with returns on paid advertising, Twitter is damaging genuine engagement, while pharma's buying power is quoshing the opportunity for balanced conversations, say
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.